<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734405</url>
  </required_header>
  <id_info>
    <org_study_id>ProF-001 IIb-III</org_study_id>
    <nct_id>NCT04734405</nct_id>
  </id_info>
  <brief_title>A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)</brief_title>
  <official_title>Phase IIb/III Parallel-arm, Random., Active-controlled, Double-blind, Double-dummy, Multicenter, Non-inferiority Study in Patients With RVVC to Compare Efficacy, Safety and Tolerability of Topically Administered ProF-001 to Oral Fluconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProFem GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Montavit Ges.m.b.H.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ProFem GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, multi-center, active-controlled, double-blind,&#xD;
      double-dummy, multicenter, non-inferiority study comparing the clinical efficacy, safety and&#xD;
      tolerability of ProF-001 to fluconazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized in a 1:1 ratio to receive either ProF-001 or fluconazole&#xD;
      for the treatment of RVVC.&#xD;
&#xD;
      Patients diagnosed with RVVC will be randomized to either ProF-001 or fluconazole treatment.&#xD;
      Treatment schedule will start with an induction period of 10 (+4) days followed by a six&#xD;
      months maintenance period and a subsequent 6 months follow-up (observation) period after end&#xD;
      of active treatment.&#xD;
&#xD;
      Any episode of VVC grade &gt; = 3 and positive vaginal smear (native or KOH) with budding&#xD;
      yeasts, pseudohyphae or hyphae from test of cure (TOC) visit onwards will be considered as&#xD;
      relapse of VVC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel-arm, Randomized, Active-controlled, Double-blind, Double-dummy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with at least one episode of clinical relapse of VVC during the 12 months study period.</measure>
    <time_frame>after 12 months</time_frame>
    <description>Registration of the number of patients with a clinical relapse within 12 months after randomization, clinical relapse of VVC is defined as severity score of VVC grade ≥ 3 with positive vaginal smear (native or KOH) with budding yeast or hyphae)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical cure (absence of signs and symptoms of VVC) at 6, 8, 10 and 12 months after randomization</measure>
    <time_frame>6, 8, 10, 12 months</time_frame>
    <description>Registration of the number of clinically cured patients throughout the study period by determination of severity score values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clinical cure (defined as absence of signs and symptoms of VVC) at the test of cure visit, day 10 (+ 4 days)</measure>
    <time_frame>after 2 weeks</time_frame>
    <description>Registration of patients with a severity score value of 0 after therapy of the acute phase at TOC visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome of time to termination of clinical symptoms using the 11-point numeric rating scale (NRS) for burning, itching, soreness/irritation</measure>
    <time_frame>within 2 weeks after randomization</time_frame>
    <description>Registration of duration of the acute episode by decrease of NRS values in a self-assessment tool, reported in a paper diary or an electronic patient reported outcome (ePRO) system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom relief reported by patients within the first 6 to 12 hours and following day after first application. Symptom relief as improvement of ≥ 2 points of symptoms compared to pre-treatment in the NRS.</measure>
    <time_frame>48 hours</time_frame>
    <description>Registration of rapid pain release by a patient reported outcome tool by measuring the decrease of NRS values for burning, itching, soreness/irritation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement of patient reported health related quality of life score at the end of the observation period using the EQ-5D questionnaire</measure>
    <time_frame>0, 6 and12 months</time_frame>
    <description>Registration of changes of health related quality of life (HRQoL)- score values at 0, 6 and 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Sexual function related to pain and improvement thereof (see Annex I)</measure>
    <time_frame>0, 6 and12 months</time_frame>
    <description>Evaluation of sexual function by changes of score values in a questionnaire regarding sexual function after 0, 6 and 12 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Recurrent Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>ProF-001 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProF-001 Group:&#xD;
• During induction period: app. 5 g of ProF-001 for 6 days (twice daily app. 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of app. 2.5 g of ProF-001 at bedtime and 1 placebo capsule on days 1, 4, and 7 and&#xD;
• During maintenance period: 2 doses of app. 2.5 g of ProF-001 per week for 22 weeks (total of 44 single doses) and 1 placebo capsule per week for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluconazole Group:&#xD;
During induction period:&#xD;
1 Fluconazole 150 mg capsule on days 1, 4, and 7 and a daily dose of app. 5 g of placebo cream for 6 days (twice daily 2.5 g vulvar/ intravaginal application of cream), followed by 4 days of 2.5 g of placebo cream at bedtime and&#xD;
During maintenance period:&#xD;
capsule of fluconazole 150 mg per week for 24 weeks and two doses of 2.5 g of placebo cream per week for 22 weeks (total of 44 single doses)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prof-001</intervention_name>
    <description>Prof-001 cream</description>
    <arm_group_label>ProF-001 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole 150 mg</intervention_name>
    <description>Fluconazole capsule</description>
    <arm_group_label>Fluconazole Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>ointment base to mimic Prof-001</description>
    <arm_group_label>Fluconazole Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>encapsulated lactose powder to mimic 150 mg fluconazole capsule</description>
    <arm_group_label>ProF-001 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients ≥ 18 years&#xD;
&#xD;
          -  Patients suffering from an acute episode in RVVC, characterized by:&#xD;
&#xD;
          -  Positive vaginal smear (native or KOH) for budding yeasts and/or (pseudo-) hyphae,&#xD;
             normal or intermediate flora&#xD;
&#xD;
          -  Two or more of the following signs and symptoms of VVC that are characterized as&#xD;
             moderate or severe: itching, burning, irritation, edema, redness, or&#xD;
             excoriation/fissure (Table 2).&#xD;
&#xD;
          -  At least 3 previous episodes of VVC during the last 12 months (i.e. at least 4&#xD;
             episodes including the current episode)&#xD;
&#xD;
          -  Readiness for sexual abstinence from start of treatment until test of cure (TOC) -&#xD;
             visit&#xD;
&#xD;
          -  Ability to understand trial instructions and rating scales as well as ability to&#xD;
             comply with treatment&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to clotrimazole, diclofenac, fluconazole or any other&#xD;
             ingredient of the investigational medicinal product&#xD;
&#xD;
          -  Pregnancy or breast feeding at time of screening (for all females of childbearing&#xD;
             potential, negative pregnancy test at screening and monthly during active treatment&#xD;
             period will be performed). Females in childbearing potential must use adequate&#xD;
             contraception during the active treatment period (sexual abstinence is an accepted&#xD;
             method of birth control)&#xD;
&#xD;
          -  Menstrual bleeding (spotting is not an exclusion criterion) during the first three&#xD;
             days of treatment during the induction period&#xD;
&#xD;
          -  Acute cystitis diagnosed by anamnesis and urinary dip stick (positive for leukocytes&#xD;
             and nitrites) during screening examination&#xD;
&#xD;
          -  Patients with other infectious causes of vulvovaginitis assessed during gynecological&#xD;
             examination at screening (e.g., bacterial vaginosis, Trichomonas vaginalis, Herpes&#xD;
             simplex)&#xD;
&#xD;
          -  Patients with other clinical gynecological abnormalities, such as infections of the&#xD;
             upper urogenital tract (pelvic inflammatory disease, adnexitis) or known high-grade&#xD;
             cervical dysplasia at screening&#xD;
&#xD;
          -  Subjects with another vaginal or vulvar condition that would confound the&#xD;
             interpretation of clinical response (e.g. lichen sclerosus, neuropathic pain, herpes&#xD;
             zoster)&#xD;
&#xD;
          -  Treatment with antimycotics (systemic or vaginal) within the prior 3 days of&#xD;
             randomization or during study period other than IMP (investigational medicinal&#xD;
             product)&#xD;
&#xD;
          -  Chronic (daily) use of non-steroidal anti-inflammatory medication during induction and&#xD;
             maintenance period (&gt;4 weeks)&#xD;
&#xD;
          -  Vaginal or oral antibiotic treatment during induction period&#xD;
&#xD;
          -  Vaginal use of corticosteroids, chronic systemic (oral, rectal or intravenous) use of&#xD;
             corticosteroids during treatment and follow-up period (≥ 5 mg oral prednisolone/d or&#xD;
             equivalent dose &gt; 4 weeks). Topical dermal (except vulvar), intranasal or inhalative&#xD;
             corticosteroids for allergy, asthma or chronic obstructive pulmonary disease allowed.&#xD;
&#xD;
          -  Vaginal use of antihistaminic drugs during induction period&#xD;
&#xD;
          -  Patients receiving anti-estrogen treatment for breast cancer, patients receiving&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption.&quot;&#xD;
&#xD;
          -  Active malignancy (except non-melanoma skin cancer, or carcinoma in situ of cervix) or&#xD;
             current treatment with anticancer therapy (chemotherapy, immunotherapy, radiotherapy,&#xD;
             hormone therapy for cancer treatment, targeted therapy or gene therapy)&#xD;
&#xD;
          -  Known major uncontrolled medical disorder(s) that renders the subject unsuitable for&#xD;
             participation in the study, including but not limited to: comorbid condition with an&#xD;
             estimated life expectancy of ≤ 12 months, known acquired immune deficiency syndrome,&#xD;
             patients with chronic kidney disease on dialysis, patients with severe pulmonary&#xD;
             (requiring home oxygen, uncontrolled COPD (chronic obstructive pulmonary disease) Gold&#xD;
             III/ IV) or cardiovascular conditions (heart failure NYHA IV)&#xD;
&#xD;
          -  Participation in another interventional clinical trial within the last 30 days&#xD;
&#xD;
          -  Employee at the study site, spouse/partner or relative of any study staff (e.g.,&#xD;
             investigator, sub-investigators, or study nurse) or relationship to the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Kiss, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik für Frauenheilkunde</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Noe, Dr.</last_name>
    <phone>+43-676 7203070</phone>
    <email>marion.noe@profem.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghazaleh Gouya, Doz. Dr.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ordination Dr. Nehoda</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Nehoda, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Shihab</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Gynäkologie und Geburthilfe, Uni-Klinik IBK</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Marth, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Mayr</name>
      <address>
        <city>Kufstein</city>
        <state>Tirol</state>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mayr, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Peter Brock</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Brock, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Fischer</name>
      <address>
        <city>Bregenz</city>
        <state>Vorarlberg</state>
        <zip>6900</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Fischer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde, AKH</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Kiss, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambulatorium für Pilzinfektionen und andere infektiöse venero-dermatologische Erkrankungen</name>
      <address>
        <city>Wien</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Stary, Prof.Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Provita Sp. z o.o. Fabryczna 13 D</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariusz Kiecka, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CMR</name>
      <address>
        <city>Katowice</city>
        <zip>40-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Nowak, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Kobiety Komed,</name>
      <address>
        <city>Kielce</city>
        <zip>25-435</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakub Wyroba, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Komed</name>
      <address>
        <city>Kielce</city>
        <zip>25-435</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Bryła, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PZS Oleśnica</name>
      <address>
        <city>Oleśnica</city>
        <zip>56-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Kobierzycki, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fem-Med</name>
      <address>
        <city>Poznań</city>
        <zip>60-512</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Hassan-Bartz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaja Poradnie Lekarskie</name>
      <address>
        <city>Poznań</city>
        <zip>61-251</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Wiza, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bonus 2001 Sp. z o.o. Sp. K.</name>
      <address>
        <city>Skórzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Kroczek-Grządzielska, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabinety Lekarskie SIGNUM</name>
      <address>
        <city>Skórzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wioletta Meissner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum medyczne Lux MED</name>
      <address>
        <city>Warsaw</city>
        <zip>02-672</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Kus, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astimed Sp. z o.o.,</name>
      <address>
        <city>Warszawa</city>
        <zip>01-875</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilla Szymankiewicz, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne LUX MED Swidnicka 40</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-024</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Kobierzycki, MD Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DC-MED., Dworcowa 5</name>
      <address>
        <city>Świdnica</city>
        <zip>58-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zbigniew Wróbel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MILLY s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Milly, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BESME s.r.o</name>
      <address>
        <city>Bánovce Nad Bebravou</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Baskova, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynedur s.r.o.</name>
      <address>
        <city>Dubnica Nad Váhom</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Durkech, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MCM GYNPED s.r.o.</name>
      <address>
        <city>Dubnica Nad Váhom</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ctirad Mokras, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyncentrum Nitra s.r.o.</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Uharcek, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GYNAMA s.r.o.</name>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milos Paskala, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BrenCare s.r.o</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Brenisin, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GYNECARE s.r.o.</name>
      <address>
        <city>Púchov</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubos Durkech, MuDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyneka s.r.o., Privatna gynekologicko porodnicka ambulancia</name>
      <address>
        <city>Trenčín</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Jankovsky, MUDr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent VVC</keyword>
  <keyword>RVVC</keyword>
  <keyword>Vulvovaginal candidiasis</keyword>
  <keyword>ProF-001</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Vulvovaginitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

